 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...211212213214215216217218219220221...235236» |
- | Folotyn (pralatrexate) / Aurobindo
Enrollment change, Combination therapy: Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies (clinicaltrials.gov) - Dec 17, 2014
P2, N=37, Recruiting, Sponsor: Spectrum Pharmaceuticals, Inc
N=20 --> 37
- ||| Alymsys (bevacizumab-maly) - Amneal, Pharmaceutical Libbs, Grupo Insud, Nichi / Iko, Stada
Enrollment open: Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN (clinicaltrials.gov) - Dec 17, 2014
P1, N=100, Recruiting, Sponsor: mAbxience S.A
N=20 --> 37 Not yet recruiting --> Recruiting
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
New P2 trial, Combination therapy, Metastases: REGAIN: Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study (clinicaltrials.gov) - Dec 16, 2014
P2, N=60, Not yet recruiting, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
- Avastin (bevacizumab) / Roche
Enrollment change, Trial initiation date, Trial primary completion date, Combination therapy: Avastin in Combination With Chemotherapy for RAS Mutant Unresectable Colorectal Liver-limited Metastases (clinicaltrials.gov) - Dec 12, 2014
P4, N=150, Recruiting, Sponsor: Xu jianmin
Not yet recruiting --> Recruiting N=300 --> 150 | Initiation date: Jun 2009 --> Jun 2011 | Trial primary completion date: Mar 2014 --> Dec 2014
- Erbitux (cetuximab) / Eli Lilly
Enrollment closed, Trial primary completion date, Metastases: CEBIFOX: Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 12, 2014
P2, N=59, Active, not recruiting, Sponsor: Martin Schuler, Prof. Dr. med.
N=300 --> 150 | Initiation date: Jun 2009 --> Jun 2011 | Trial primary completion date: Mar 2014 --> Dec 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2011 --> Mar 2015
- || Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: STEAM: Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 10, 2014
P2, N=280, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2011 --> Mar 2015 Trial primary completion date: Dec 2017 --> Dec 2016
- ||||| 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment change, Trial initiation date, Metastases: Rectal Cancer, Adjuvant Chemotherapy, FOLFOX(5-fluorouracil/Leucovorin/Oxaliplatin), Total Mesorectal Excision (clinicaltrials.gov) - Dec 10, 2014
P3, N=580, Not yet recruiting, Sponsor: Yonsei University
Trial primary completion date: Dec 2017 --> Dec 2016 N=1008 --> 580 | Initiation date: Jul 2014 --> Dec 2014
- New P2/3 trial, Metastases: Induction Chemotherapy, FOLFIRINOX Followed With Concurrent Capecitabine and Radiation Therapy in Inoperable Locally Advanced Cancer of the Pancreas (clinicaltrials.gov) - Dec 8, 2014
P2/3, N=1, Recruiting, Sponsor: Assiut University
- Rituxan (rituximab) / Roche
Trial primary completion date: LeMLAR: Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas (clinicaltrials.gov) - Dec 6, 2014
P1/2, N=44, Recruiting, Sponsor: University Hospital, Essen
N=1008 --> 580 | Initiation date: Jul 2014 --> Dec 2014 Trial primary completion date: Feb 2015 --> Jun 2017
- ||| Erbitux (cetuximab) / Eli Lilly
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: Everest 2: Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer (clinicaltrials.gov) - Dec 6, 2014
P2, N=375, Active, not recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
Trial primary completion date: Feb 2015 --> Jun 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2014 --> Mar 2015
- 5-fluorouracil / Generic mfg., metformin / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date, Metastases: Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer (clinicaltrials.gov) - Dec 5, 2014
P2, N=43, Recruiting, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2014 --> Mar 2015 Trial primary completion date: Sep 2014 --> May 2015
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial primary completion date, Metastases: COMETS: Trial Comparing Two Two Sequences of Therapy in Colorectal Metastatic Patients (clinicaltrials.gov) - Dec 5, 2014
P3, N=350, Recruiting, Sponsor: Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Trial primary completion date: Sep 2014 --> May 2015 Trial primary completion date: Dec 2013 --> Nov 2014
- || oxaliplatin liposomal (L-OHP) / Mebiopharm
Trial primary completion date: Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma (clinicaltrials.gov) - Dec 5, 2014
P1/2, N=62, Active, not recruiting, Sponsor: Mebiopharm Co., Ltd
Trial primary completion date: Dec 2013 --> Nov 2014 Trial primary completion date: Jun 2012 --> Oct 2012
- Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment change, Trial initiation date, Trial withdrawal, Metastases: Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 5, 2014
P2, N=0, Withdrawn, Sponsor: NSABP Foundation Inc
Trial primary completion date: Jun 2012 --> Oct 2012 N=120 --> 0 | Initiation date: Feb 2014 --> Nov 2014 | Not yet recruiting --> Withdrawn
- ||||| veliparib (ABT-888) / AbbVie
New P2 trial, Metastases: Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 5, 2014
P2, N=120, Recruiting, Sponsor: AbbVie
- | Avastin (bevacizumab) / Roche
Trial completion: TOSCA: FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer (clinicaltrials.gov) - Nov 28, 2014
P3, N=3756, Completed, Sponsor: Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
N=120 --> 0 | Initiation date: Feb 2014 --> Nov 2014 | Not yet recruiting --> Withdrawn Recruiting --> Completed
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date: BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial (clinicaltrials.gov) - Nov 24, 2014
P2, N=25, Recruiting, Sponsor: howard safran
Recruiting --> Completed Trial primary completion date: Feb 2015 --> Jun 2015
- leucovorin calcium / Generic mfg.
Enrollment change, Trial primary completion date, Combination therapy: Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas (clinicaltrials.gov) - Nov 24, 2014
P1, N=24, Recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Feb 2015 --> Jun 2015 N=39 --> 24 | Trial primary completion date: Oct 2018 --> Oct 2017
- New P2 trial: Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers (clinicaltrials.gov) - Nov 20, 2014
P2, N=50, Not yet recruiting, Sponsor: Washington University School of Medicine
- Enrollment closed: Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 19, 2014
P2, N=66, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=39 --> 24 | Trial primary completion date: Oct 2018 --> Oct 2017 Recruiting --> Active, not recruiting
- | Phase classification, Trial initiation date, Trial primary completion date: Mature B-Cell Lymphoma And Leukemia Study III (clinicaltrials.gov) - Nov 18, 2014
P2/3, N=60, Recruiting, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Active, not recruiting Phase classification: P3 --> P2/3 | Initiation date: Jan 2010 --> Jan 2009 | Trial primary completion date: Jun 2016 --> Oct 2022
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma (clinicaltrials.gov) - Nov 18, 2014
P1, N=18, Not yet recruiting, Sponsor: University of California, Davis
- leucovorin calcium / Generic mfg.
Trial completion: Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer (clinicaltrials.gov) - Nov 18, 2014
P2, N=80, Completed, Sponsor: Washington University School of Medicine
Phase classification: P3 --> P2/3 | Initiation date: Jan 2010 --> Jan 2009 | Trial primary completion date: Jun 2016 --> Oct 2022 Active, not recruiting --> Completed
- || ensituximab (NEO-102) / ImmunityBio
Trial primary completion date, Metastases: QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer (clinicaltrials.gov) - Nov 17, 2014
P1/2, N=90, Recruiting, Sponsor: Precision Biologics, Inc
Active, not recruiting --> Completed Trial primary completion date: Oct 2014 --> Oct 2016
- ||| Metastases: LAPC-1: Efficacy and Feasibility of Combining FOLFIRINOX and Stereotactic Radiotherapy for Patients With Irresectable Locally Advanced Pancreatic Cancer. (clinicaltrials.gov) - Nov 17, 2014
P=N/A, N=51, Recruiting, Sponsor: Foundation for Liver Research
- ||||| Biomarker, New P2 trial, MSi-H Biomarker, PD(L)-1 Biomarker: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Nov 14, 2014
P2, N=1680, Not yet recruiting, Sponsor: Hoffmann-La Roche
- Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy, Metastases: Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Nov 13, 2014
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2014 --> Oct 2016 Trial primary completion date: Aug 2014 --> Nov 2014
- | NK012 / Nippon Kayaku
Trial completion, Combination therapy, Metastases: Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer (clinicaltrials.gov) - Nov 13, 2014
P1, N=35, Completed, Sponsor: Nippon Kayaku Co.,Ltd.
Trial primary completion date: Aug 2014 --> Nov 2014 Active, not recruiting --> Completed
- || prexasertib (ACR-368) / Acrivon Therap
Trial primary completion date, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (clinicaltrials.gov) - Nov 12, 2014
P1, N=70, Recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Trial primary completion date: Jun 2016 --> Oct 2017
- Erbitux (cetuximab) / Eli Lilly
Enrollment change, Trial termination, Trial primary completion date, Metastases: An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer (clinicaltrials.gov) - Nov 11, 2014
P=N/A, N=165, Terminated, Sponsor: Merck KGaA
Trial primary completion date: Jun 2016 --> Oct 2017 N=100 --> 165 | Recruiting --> Terminated | Trial primary completion date: Apr 2014 --> Jul 2013; The study was discontinued due to slow recruitment and subjects not completing follow up period.
- GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis
Trial primary completion date, Tumor cell: Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas (clinicaltrials.gov) - Nov 6, 2014
P=N/A, N=18, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=100 --> 165 | Recruiting --> Terminated | Trial primary completion date: Apr 2014 --> Jul 2013; The study was discontinued due to slow recruitment and subjects not completing follow up period. Trial primary completion date: Jul 2014 --> Jul 2016
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
New P4 trial: Safety of Orectalip (clinicaltrials.gov) - Nov 6, 2014
P4, N=20, Completed, Sponsor: Sinphar Pharmaceutical Co., Ltd
- Avastin (bevacizumab) / Roche, apitolisib (GDC-0980) / Roche
Trial primary completion date, Combination therapy, Metastases: GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Nov 5, 2014
P1, N=33, Active, not recruiting, Sponsor: Genentech, Inc.
Trial primary completion date: Jul 2014 --> Jul 2016 Trial primary completion date: Apr 2014 --> Jul 2015
- crenolanib (ARO-002) / AROG
Enrollment open, Combination therapy: Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies (clinicaltrials.gov) - Nov 5, 2014
P1, N=24, Recruiting, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Apr 2014 --> Jul 2015 Not yet recruiting --> Recruiting
- Enrollment change, Trial termination, Trial primary completion date, Combination therapy, Metastases: XELOX Versus FOLFOX for Advanced Gastric Cancer (AGC) (clinicaltrials.gov) - Nov 4, 2014
P3, N=42, Terminated, Sponsor: Dong-A University Hospital
Not yet recruiting --> Recruiting N=438 --> 42 | Recruiting --> Terminated | Trial primary completion date: Dec 2015 --> Sep 2014; Poor enrollment of patients
- |||| onartuzumab (RG3638) / Roche
Trial completion, Trial primary completion date, Combination therapy, Metastases: A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer (clinicaltrials.gov) - Nov 4, 2014
P2, N=123, Completed, Sponsor: Hoffmann-La Roche
N=438 --> 42 | Recruiting --> Terminated | Trial primary completion date: Dec 2015 --> Sep 2014; Poor enrollment of patients Active, not recruiting --> Completed | Trial primary completion date: May 2014 --> Oct 2014
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial completion, Trial primary completion date, Metastases: FOLFOX Followed by FOLFIRI or Reverse Sequence Treatment in Advanced Gastric Cancer (AGC) (clinicaltrials.gov) - Nov 4, 2014
P2, N=80, Completed, Sponsor: Dong-A University Hospital
Active, not recruiting --> Completed | Trial primary completion date: May 2014 --> Oct 2014 Recruiting --> Completed | Trial primary completion date: Sep 2012 --> Sep 2013
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., sorafenib / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: Sorafenib + mFOLFOX for Hepatocellular Carcinoma (clinicaltrials.gov) - Oct 31, 2014
P2, N=40, Recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Completed | Trial primary completion date: Sep 2012 --> Sep 2013 Trial primary completion date: Feb 2015 --> Dec 2015
- Tasigna (nilotinib) / Novartis, Inhibikase
Enrollment change, Trial withdrawal: Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia (clinicaltrials.gov) - Oct 31, 2014
P2, N=0, Withdrawn, Sponsor: Mayo Clinic
Trial primary completion date: Feb 2015 --> Dec 2015 N=44 --> 0 | Active, not recruiting --> Withdrawn
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial: RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301). (clinicaltrials.gov) - Oct 31, 2014
P2, N=110, Recruiting, Sponsor: Clinical Research Support Center Kyush
- Trial primary completion date: A Study Comparing Adjuvant Chemotherapy Versus Observation for Patients With Rectal Adenocarcinoma After Neoadjuvant Chemo-Radiotherapy Treatment. (clinicaltrials.gov) - Oct 30, 2014
P3, N=309, Recruiting, Sponsor: Instituto do Cancer do Estado de S
N=44 --> 0 | Active, not recruiting --> Withdrawn Trial primary completion date: Sep 2013 --> Sep 2015
- foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma
Trial primary completion date, Combination therapy, Metastases: Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Oct 30, 2014
P1, N=24, Recruiting, Sponsor: Prism Pharma Co., Ltd.
Trial primary completion date: Sep 2013 --> Sep 2015 Trial primary completion date: Oct 2014 --> Apr 2015
- | Enrollment change, Metastases: FLOT4: 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer (clinicaltrials.gov) - Oct 30, 2014
P2/3, N=714, Recruiting, Sponsor: Krankenhaus Nordwest
Trial primary completion date: Oct 2014 --> Apr 2015 N=590 --> 714
- | gedatolisib (PF-05212384) / Celcuity
Phase classification, Metastases: A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 30, 2014
P2, N=185, Recruiting, Sponsor: Pfizer
N=590 --> 714 Phase classification: P1/2 --> P2
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Trial primary completion date, Combination therapy, Metastases: GP28328: A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Oct 27, 2014
P1, N=180, Recruiting, Sponsor: Genentech, Inc.
Phase classification: P1/2 --> P2 Trial primary completion date: Sep 2014 --> Feb 2016
- ipatasertib (RG7440) / Roche
Enrollment open, Enrollment change, Combination therapy, Metastases: A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Oct 24, 2014
P2, N=150, Recruiting, Sponsor: Genentech, Inc.
Trial primary completion date: Sep 2014 --> Feb 2016 Active, not recruiting --> Recruiting | N=122 --> 150
- Otrexup (methotrexate) / Halozyme, Rituxan (rituximab) / Roche
Trial primary completion date: Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma (clinicaltrials.gov) - Oct 23, 2014
P2, N=28, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Recruiting | N=122 --> 150 Trial primary completion date: Jul 2018 --> Jul 2016
- Cyramza (ramucirumab) / Eli Lilly
Trial primary completion date, Metastases: A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer (clinicaltrials.gov) - Oct 22, 2014
P1, N=9, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Jul 2018 --> Jul 2016 Trial primary completion date: Oct 2014 --> Mar 2015
- || Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: STEAM: Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 22, 2014
P2, N=280, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Oct 2014 --> Mar 2015 Trial primary completion date: Nov 2016 --> Dec 2017
- || andecaliximab (GS-5745) / Gilead
Enrollment change, Trial primary completion date, Combination therapy, Monotherapy, Metastases: Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Oct 22, 2014
P1, N=111, Recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Nov 2016 --> Dec 2017 N=199 --> 111 | Trial primary completion date: Jun 2015 --> Oct 2015